- Replys to Correspondence Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Jing Zeng, Jian-Gao Fan
- Clin Mol Hepatol. 2025;31(2):e218-e220.
- Letters to the Editor What is new in the 2024 Chinese guidelines for fatty liver disease?
- Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan
- DOI: 10.3350/cmh.2024.1165 [Epub ahead of print]
- Editorials A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Jing Zeng, Jian-Gao Fan
- Clin Mol Hepatol. 2025;31(2):610-614.
- Replys to Correspondence Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
- Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
- Clin Mol Hepatol. 2024;30(4):1039-1041.
- Editorials Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
- Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
- Clin Mol Hepatol. 2024;30(4):649-652.
- Reviews Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
- Yi-wen Shi, Jian-Gao Fan
- Clin Mol Hepatol. 2023;29(Suppl):S228-S243.
- Editorials Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?
- Qian Jin, Rui-Xu Yang, Jian-Gao Fan
- Clin Mol Hepatol. 2022;28(3):473-477.
- Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
- Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan
- Clin Mol Hepatol. 2021;27(1):83-86.